Literature DB >> 21774036

Personality diagnostic questionnaire 4+ is not useful as a screener in clinical practice.

Rob J M de Reus1, Julia F van den Berg, Paul M G Emmelkamp.   

Abstract

In clinical practice, the combination of brief, cost effective, valid and reliable assessment of personality disorders (PDs) is highly important. Substantial budget cuts require optimal use of the clinician's time. PDs are related with high axis I comorbidity, poorer therapy outcome and increased health service costs. In an effort to find a screening questionnaire that meets both the demands of cost-effectiveness and methodological soundness, we investigated the use of the Personality Diagnostic Questionnaire 4+ (PDQ-4+) as a first step in a two-step diagnostic procedure. As the second step, we used the Structured Clinical Interview of DSM-IV Axis II Personality Disorders (SCID-II) as criterion measure. Our results show that the positive predictive power of the PDQ-4+ is rather low, resulting in a large number of false positives. Therefore, its added value is poor in comparison with administering the SCID-II in the first place. Also, the value of the two validity scales of the PDQ-4+ is highly questionable. We therefore conclude that the PDQ-4+ should not be used in clinical practice as a screening instrument for PD assessment.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21774036     DOI: 10.1002/cpp.766

Source DB:  PubMed          Journal:  Clin Psychol Psychother        ISSN: 1063-3995


  2 in total

1.  Prevalence of DSM-IV personality disorders in patients with chronic fatigue syndrome: a controlled study.

Authors:  Stefan Kempke; Filip Van Den Eede; Chris Schotte; Stephan Claes; Peter Van Wambeke; Boudewijn Van Houdenhove; Patrick Luyten
Journal:  Int J Behav Med       Date:  2013-06

Review 2.  Personality Disorders in Older Adults: a Review of Epidemiology, Assessment, and Treatment.

Authors:  Krystle A P Penders; Inge G P Peeters; Job F M Metsemakers; Sebastiaan P J van Alphen
Journal:  Curr Psychiatry Rep       Date:  2020-02-06       Impact factor: 5.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.